loading page

Use of a sodium--glucose cotransporter 2 inhibitor, empagliflozin, in a patient with Rabson-Mendehall Syndrome
  • +2
  • SARAH SIMAAN SANTOS,
  • Luana Aparecida Ramaldes,
  • Monica Gabbay,
  • Regina Moisés,
  • Sergio Dib
SARAH SIMAAN SANTOS
Federal University of Sao Paulo
Author Profile
Luana Aparecida Ramaldes
Federal University of Sao Paulo
Author Profile
Monica Gabbay
Federal University of Sao Paulo
Author Profile
Regina Moisés
Federal University of Sao Paulo
Author Profile
Sergio Dib
Federal University of São Paulo
Author Profile

Abstract

Rabson-Mendenhall Syndrome (RMS) is a rare condition caused by mutations in the insulin receptor gene. The affected patients have severe insulin resistance and the treatment is challenging due to difficulties in reaching satisfactory glycemic control. We report a case where iSGT2 was used as an adjunct therapy to insulin.